This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medidata Executives Participate In Upcoming Investor Conferences

Medidata Solutions (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Tarek Sherif, chairman and chief executive officer, and Cory Douglas, chief financial officer, will participate in two upcoming investor conferences in September.

Raymond James European Investors North American Equities Conference
Date: Tuesday, September 10, 2013 at 10:55 a.m. UK Time (5:55 a.m. ET)
Location: London, England
Participants: Tarek Sherif and Cory Douglas
 

Deutsche Bank 2013 Technology Conference
Date: Wednesday, September 11, 2013 at 7:30 a.m. PT (10:30 a.m. ET)
Location: Las Vegas, NV

Participant: Cory Douglas

Live audio webcasts for the Raymond James European Investors North American Equities Conference and Deutsche Bank 2013 Technology Conference will be available on the “Investor” section of Medidata’s website at http://investor.mdsol.com. Please visit the website at least 15 minutes prior to each event to register, download and install any necessary audio or video software to access the presentations. For those unable to participate in the live webcasts, replays will be archived on the “Investor” section of Medidata’s website at http://investor.mdsol.com for a limited period of time following the conferences.

About Medidata Solutions

Medidata Solutions is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of our global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs